These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 2168281)
1. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone. Fox ME; Smith PJ Cancer Res; 1990 Sep; 50(18):5813-8. PubMed ID: 2168281 [TBL] [Abstract][Full Text] [Related]
2. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity. Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921 [TBL] [Abstract][Full Text] [Related]
3. Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells. Del Bino G; Darzynkiewicz Z Cancer Res; 1991 Feb; 51(4):1165-9. PubMed ID: 1997159 [TBL] [Abstract][Full Text] [Related]
4. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551 [TBL] [Abstract][Full Text] [Related]
5. Reduced DNA break formation and cytotoxicity of the topoisomerase II drug 4'-(9'-acridinylamino)methanesulfon-m-anisidide when combined with hyperthermia in human and rodent cell lines. Kampinga HH; van den Kruk G; Konings AW Cancer Res; 1989 Apr; 49(7):1712-7. PubMed ID: 2538233 [TBL] [Abstract][Full Text] [Related]
6. Cellular consequences of overproduction of DNA topoisomerase II in an ataxia-telangiectasia cell line. Smith PJ; Makinson TA Cancer Res; 1989 Mar; 49(5):1118-24. PubMed ID: 2537142 [TBL] [Abstract][Full Text] [Related]
7. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs. Epstein RJ; Smith PJ Cancer Res; 1988 Jan; 48(2):297-303. PubMed ID: 2825970 [TBL] [Abstract][Full Text] [Related]
8. Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells. Markovits J; Pommier Y; Kerrigan D; Covey JM; Tilchen EJ; Kohn KW Cancer Res; 1987 Apr; 47(8):2050-5. PubMed ID: 3030540 [TBL] [Abstract][Full Text] [Related]
9. Amsacrine-induced lesions in DNA and their modulation by novobiocin and 2,4-dinitrophenol. Shibuya ML; Buddenbaum WE; Don AL; Utsumi H; Suciu D; Kosaka T; Elkind MM Cancer Res; 1991 Jan; 51(2):573-80. PubMed ID: 1985775 [TBL] [Abstract][Full Text] [Related]
10. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects. De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987 [TBL] [Abstract][Full Text] [Related]
11. [Poisons of DNA topoisomerases I and II]. Charcosset JY; Soues S; Laval F Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034 [TBL] [Abstract][Full Text] [Related]
12. DNA double-strand break repair pathways and cellular tolerance to inhibitors of topoisomerase II. Caldecott K; Banks G; Jeggo P Cancer Res; 1990 Sep; 50(18):5778-83. PubMed ID: 2168280 [TBL] [Abstract][Full Text] [Related]
13. Topoisomerase II-dependent and -independent mechanisms of etoposide resistance in Chinese hamster cell lines. Spiridonidis CA; Chatterjee S; Petzold SJ; Berger NA Cancer Res; 1989 Feb; 49(3):644-50. PubMed ID: 2535964 [TBL] [Abstract][Full Text] [Related]
14. Abrogation by novobiocin of cytotoxicity due to the topoisomerase II inhibitor amsacrine in Chinese hamster cells. Utsumi H; Shibuya ML; Kosaka T; Buddenbaum WE; Elkind MM Cancer Res; 1990 May; 50(9):2577-81. PubMed ID: 2158394 [TBL] [Abstract][Full Text] [Related]
15. Phorbol ester effects on topoisomerase II activity and gene expression in HL-60 human leukemia cells with different proclivities toward monocytoid differentiation. Zwelling LA; Hinds M; Chan D; Altschuler E; Mayes J; Zipf TF Cancer Res; 1990 Nov; 50(22):7116-22. PubMed ID: 2171756 [TBL] [Abstract][Full Text] [Related]
16. Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells. Zwelling LA; Chan D; Hinds M; Mayes J; Silberman LE; Blick M Cancer Res; 1988 Dec; 48(23):6625-33. PubMed ID: 2846155 [TBL] [Abstract][Full Text] [Related]
17. Copper-dependent oxidative and topoisomerase II-mediated DNA cleavage by a netropsin/4'-(9-acridinylamino)methanesulfon-m-anisidide combilexin. Henichart JP; Waring MJ; Riou JF; Denny WA; Bailly C Mol Pharmacol; 1997 Mar; 51(3):448-61. PubMed ID: 9058600 [TBL] [Abstract][Full Text] [Related]
18. Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells. Bakic M; Chan D; Freireich EJ; Marton LJ; Zwelling LA Cancer Res; 1987 Dec; 47(24 Pt 1):6437-43. PubMed ID: 2824033 [TBL] [Abstract][Full Text] [Related]
19. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Pommier Y; Kerrigan D; Schwartz RE; Swack JA; McCurdy A Cancer Res; 1986 Jun; 46(6):3075-81. PubMed ID: 3009009 [TBL] [Abstract][Full Text] [Related]
20. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Holm C; Covey JM; Kerrigan D; Pommier Y Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]